Drugs / FAZAMOREXANT
last change Aug 2025 re-read 2 minutes ago

FAZAMOREXANT

also known as YZJ-1139

Small molecule

Developed for
insomnia
Investigated by
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Trials 9 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 16 trials
Phase 1 NCT06680531 Aug → Sep 2024 insomnia Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Completed No outcome recorded
Phase 1 NCT06671470 Aug → Sep 2024 insomnia Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Completed No outcome recorded
Phase 1 NCT06671444 Jun → Oct 2024 impaired renal function disease, insomnia Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Completed No outcome recorded
Phase 1 NCT06671509 Mar → Apr 2024 insomnia Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Completed No outcome recorded
Phase 1 NCT06685341 Mar → Apr 2019 insomnia Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Completed No outcome recorded
Phase 1 NCT06673927 Dec 2017 → Nov 2018 insomnia Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Completed No outcome recorded
Phase 21 trial
Phase 2 NCT06680505 Aug 2019 → Sep 2020 insomnia Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Completed No outcome recorded
Phase 32 trials
Phase 3 NCT06975514 Mar → Jul 2025 insomnia Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Completed No outcome recorded
Phase 3 NCT05525637 Dec 2021 → Jul 2023 insomnia Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as FAZAMOREXANT ChEMBL registry synonym — accepted as the source's own label CHEMBL5314459
Known as YZJ-1139 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06680505
8

NCT06671509

NCT06671444

NCT06685341

NCT06975514

NCT05525637

NCT06671470

NCT06673927

NCT06680531

Modality Small molecule CHEMBL5314459
Route Oral “Single oral dose, 20 mg tablet” NCT06671444